Clinical Overview
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily or twice daily at the exact same hour every single day. Strict lifelong adherence is paramount to prevent viral rebound and resistance mutation. Do not skip doses or alter timing without specialist guidance.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, nausea, fatigue, insomnia, diarrhea, abnormal dreams (with efavirenz). Rare/Severe: Renal tubular dysfunction/Fanconi syndrome (tenofovir disoproxil), loss of bone mineral density, severe hypersensitivity (abacavir HLA-B*5701), lactic acidosis/severe hepatomegaly with steatosis, and immune reconstitution inflammatory syndrome (IRIS).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warnings: Exacerbation of Hepatitis B upon treatment discontinuation in co-infected patients. HLA-B*5701 genetic testing is mandatory prior to abacavir administration to prevent fatal hypersensitivity. Routine monitoring of renal function, bone density, viral load, and CD4 counts is essential.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Sitagliptin Phosphate 50mg & Metformin Hydrochloride 1000mg Tablets
Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Abacavir 600mg + Dolutegravir 50mg + Lamivudine 300mg Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Dolutegravir (50 Mg) + Emtricitabine (200 Mg) + Tenofovir Alafenamide (25 Mg) Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Dolutegravir (50Mg) + Lamivudine (300Mg) + Tenofovir Disoproxil Fumarate (300Mg) Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.